The National Institute of Pharmaceutical Education and Research, Ahmedabad(NIPER-A), claims to have developed new class of compounds for treatment of Type-II diabetes and also perfected the manufacturing process for it.
Its director Kiran Kalia, addressing media persons here on Wednesday, claimed that the chemical molecules developed by her institute was different from other drugs available in the market. The institute, she said, had filed application seeking patent for it.
She claimed that the drug was more efficient and cost effective than other drugs for diabetes available currently in the global market.
- GenderAnd Development: The highs and lows of women drug users in Manipur
- Experimental drug may reduce weight of obese people: Study
- One pill to ward off both diabetes, heart disease could be reality
- Once-a-month diabetes treatment may replace daily insulin jabs
- Now,quick fix drug to tackle obesity,diabetes!
- Now,a new form of insulin that can be inhaled!
The institute was, however, yet to approach the pharma companies for its commercial manufacturing and sale in the market.
Stating that her institute is also focussing on developing new drugs against tuberculosis and resistant TB strains, Kalia claimed that NIPER-A had developed as many as eight molecules exhibiting potent activity against Rifampicin-resistant strain of tuberculosis.
The institute conducts MS(Pharma) and doctoral courses. So far, a total of 284 students have passed out from the institute and 92 are currently studying for different postgraduate courses. A total of 15 students have enrolled for PhD programmes.
The institute, which is among seven national institutes set up in 2007 by the central government for postgraduate teaching and research in pharma, is currently operating from MB Institute of Mental Health in Ahmedabad. Its new building is under construction over 90 acres of land at an estimated cost of Rs. 497 crores in Chiloda village , adjacent to Indian Institute of Technology(IIT) , in Gandhinagar. It is likely to be completed by 2017 end.